IceCure Medical Highlights ProSense Breast Cancer Cryoablation at EUSOBI Conference
News related to:IceCure Medical · 1 min read
CAESAREA, Israel, October 13, 2026 /CourierPR/ -- IceCure Medical, the developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical removal, highlighted the strong engagement of European physicians at the EUSOBI Annual Scientific Meeting 2026, held in Maastricht, the Netherlands. The meeting featured multiple scientific presentations, research posters, and clinical workshops focused on ProSense® breast cancer cryoablation.
ProSense® was showcased in two key scientific sessions at the EUSOBI Annual Scientific Meeting, reflecting the growing interest in breast cancer cryoablation within Europe.
IceCure Medical also hosted two well-attended clinical workshops, led by Dr. Lucía Graña-López and Dr. Federica Di Naro, which attracted nearly 70 participants each.
Two scientific posters by ProSense® users were also presented at the meeting. Dr. Georgiana-Cristiana Camen from Romania shared the single-center efficacy and safety of percutaneous cryoablation for breast lesions, while Dr. Francesca Pugliese from Florence, Italy, discussed the role of negative CEM (Contrast Enhancement Mammography) in predicting histological response after breast cryoablation.
The EUSOBI Annual Scientific Meeting provided a platform for the exchange of clinical knowledge, research, and advances in breast imaging and treatment. The meeting's attendees were particularly interested in the potential of ProSense® for treating breast cancer, with the presentations and posters generating significant interest and engagement.
IceCure Medical, a developer of advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, is the subject of this news article. The company's flagship ProSense® system is marketed and sold worldwide for indications cleared and approved to date, including in the U.S., Europe, and Asia. ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.